5 Pharmaceutical preparations and drugs for the treatment of cancer, namely, Myelofibrosis (MF); pharmaceutical preparations and drugs for the treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Biological and chemical preparations for the treatment of cancer; Pharmaceutical products, preparations, and compounds for the prevention and treatment of cancer and tumors, treatment of blood diseases or disorders, bone and bone marrow diseases, and cancers associated with blood diseases and/or disorders; Pharmaceutical preparations and substance for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical reagents; Medical diagnostic reagents, assays, and test kits for testing of body fluids; cells, protein molecules, and molecular compounds in the nature of drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals for medical purposes; DNA damage response assets, namely, pharmaceutical preparations for the treatment of conditions associated with DNA damage, namely cancer, for medical use